Top Page
Elixinol Wellness
(Sydney:EXL)
Elixinol Wellness (EXL) vs. iShares MSCI Australia ETF (EWA)
Elixinol Wellness Business Overview & Revenue Model
Elixinol Wellness Earnings Call Summary
Elixinol Wellness Financial Statement Overview
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 15.50M | 14.96M | 8.27M | 7.05M | 9.34M |
| Gross Profit | 752.00K | 5.36M | -1.80M | -3.27M | -6.25M |
| EBITDA | -4.11M | -4.01M | -6.81M | -9.28M | -15.51M |
| Net Income | -5.50M | -1.72M | -7.51M | -10.57M | -17.02M |
Balance Sheet | |||||
| Total Assets | 15.96M | 18.45M | 11.71M | 13.48M | 25.33M |
| Cash, Cash Equivalents and Short-Term Investments | 1.41M | 1.08M | 708.00K | 2.86M | 12.65M |
| Total Debt | 3.95M | 1.94M | 1.26M | 1.83M | 2.71M |
| Total Liabilities | 8.51M | 8.42M | 5.25M | 4.33M | 6.25M |
| Stockholders Equity | 7.45M | 10.03M | 6.46M | 9.16M | 19.08M |
Cash Flow | |||||
| Free Cash Flow | -3.28M | -3.53M | -2.77M | -8.16M | -14.36M |
| Operating Cash Flow | -3.21M | -3.47M | -2.76M | -8.15M | -14.07M |
| Investing Cash Flow | -216.00K | -66.00K | -1.04M | -869.00K | 172.00K |
| Financing Cash Flow | 3.65M | 3.92M | 1.61M | -757.00K | -1.16M |
Elixinol Wellness Technical Analysis
Elixinol Wellness Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | AU$3.73M | -0.47 | -26.84% | ― | 36.60% | 85.28% | |
43 Neutral | AU$10.51M | -5.00 | -469.43% | ― | -1.25% | -188.33% | |
39 Underperform | AU$12.71M | 0.87 | -401.36% | ― | -26.49% | 61.72% |
Elixinol Wellness Corporate Events
Elixinol Wellness is positioning itself as a sustainable nutrition and wellness player with vertically integrated operations in Australia and the U.S., spanning production, manufacturing and distribution. Its brands, including The Healthy Chef, Hemp Foods Australia, Mt Elephant and Elixinol USA, give it exposure to grocery, wholesale and online retail channels for superfood, hemp and nutraceutical products.
The company’s diversified brand portfolio and multichannel distribution strategy underline an effort to deepen its presence across key nutrition and wellness verticals. By combining superfood ingredients with hemp and broader nutraceutical offerings, Elixinol aims to strengthen its market positioning in health-conscious consumer segments and drive growth in both domestic and international markets.
The most recent analyst rating on (AU:EXL) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Elixinol Wellness stock, see the AU:EXL Stock Forecast page.
Elixinol Wellness has lodged its latest corporate governance statement for the financial year ended 31 December 2025, confirming that the statement is current as of 27 February 2026 and has been approved by the board. The company has opted to publish the statement on its website and has filed the accompanying Appendix 4G, outlining how it complies with ASX Corporate Governance Council principles, including board charters, director appointment processes and executive agreements, reinforcing transparency and governance standards for investors.
The lodgement demonstrates Elixinol’s ongoing compliance with ASX listing requirements, signalling to shareholders and regulators that it maintains structured oversight and clear delineation of board and management responsibilities. By formally documenting its governance practices and making them accessible online, the company aims to support investor confidence and provide a clear verification tool for stakeholders assessing its governance framework.
The most recent analyst rating on (AU:EXL) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Elixinol Wellness stock, see the AU:EXL Stock Forecast page.
Elixinol Wellness Limited reported a 3.6% rise in revenue to $15.5 million for the year ended 31 December 2025, but its net loss attributable to owners widened sharply to $5.5 million, a 219.4% increase from the prior year. Basic and diluted loss per share deepened to 2.15 cents from 1.11 cents, and no dividends were paid or declared for either the current or previous financial periods.
The company’s balance sheet weakened, with net tangible assets per share falling from 0.13 cents to negative 0.36 cents, reflecting a swing in net tangible assets from $0.3 million to a deficit of $1.5 million. Despite the deteriorating financial position, Elixinol’s 2025 financial statements received an unmodified audit opinion, and the board formally authorised the release of the preliminary final report to the market.
The most recent analyst rating on (AU:EXL) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Elixinol Wellness stock, see the AU:EXL Stock Forecast page.
Elixinol Wellness Ltd has scheduled an investor webinar for 10:00am AEDT on Thursday 12 February 2026, where management will present the company’s Q4 FY25 results and outlook before taking questions. The session signals the company’s effort to maintain transparency with investors on recent performance and strategic direction, which may shape market expectations around its positioning in the competitive sustainable nutrition and wellness sector.
The most recent analyst rating on (AU:EXL) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Elixinol Wellness stock, see the AU:EXL Stock Forecast page.
Elixinol Wellness reported December quarter FY25 revenue of $4.1 million, up 9.5% quarter-on-quarter, contributing to full-year FY25 revenue of $15.5 million, a 3.6% increase year-on-year driven by portfolio rationalisation and a focus on higher-margin sales. The acquisition of Healthy Chef has diversified and strengthened e-commerce revenues, which rose 42% in the quarter and 24% for the year on a pro forma basis, underpinned by innovation in high-growth functional nutrition categories such as Protein Water and new flavour launches. The company has re-established its dominant role as a key hemp supplier to Australian retailers, expanding private-label supply agreements and achieving record sales at Hemp Foods Australia, while Australian Primary Hemp secured an expanded supply contract with a major grocery chain. At the same time, Elixinol has implemented a structural reduction in operating costs of about 30% versus the prior year’s December quarter and delivered underlying operating cash flow positivity, providing a lower-cost base, clearer path to profitability and a stronger platform for organic growth and potential M&A as it progresses brand resets and new product launches into 2026.
The most recent analyst rating on (AU:EXL) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Elixinol Wellness stock, see the AU:EXL Stock Forecast page.
Elixinol Wellness Limited has reported that 58,220 performance rights on issue under ASX code EXLAC have lapsed unexercised following their expiry on 15 January 2026. The expiry slightly reduces the company’s pool of potential equity-based instruments on issue, but reflects a routine adjustment to its capital structure rather than a new capital raising or buyback initiative.
The most recent analyst rating on (AU:EXL) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Elixinol Wellness stock, see the AU:EXL Stock Forecast page.
Elixinol Wellness Limited has disclosed a change in the relevant interests of director Gavin Evans, in line with ASX listing rule 3.19A.2 reporting requirements. The director, via a superannuation fund account, acquired 397,010 fully paid ordinary shares in on‑market trades on 19 and 30 December 2025 for a total consideration of $3,820.85, increasing his indirect holding from 7,407,407 to 7,804,417 shares, while his existing 50,000,000 unlisted options remain unchanged. The transactions, which did not occur during a closed trading period, modestly increase Evans’ equity exposure to the company, incrementally aligning his interests with those of other shareholders and signaling continued personal investment in Elixinol Wellness.
The most recent analyst rating on (AU:EXL) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Elixinol Wellness stock, see the AU:EXL Stock Forecast page.
Elixinol Wellness has announced a change of auditor following the Australian corporate regulator’s consent to the resignation of BDO Audit, which stepped down effective 18 December 2025 without identifying any reportable matters linked to its departure. The board has appointed RSM Australia as the company’s new auditor, with the move to be put to shareholders for ratification at the next annual general meeting, signalling a routine governance transition rather than a response to financial or compliance concerns.
The most recent analyst rating on (AU:EXL) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Elixinol Wellness stock, see the AU:EXL Stock Forecast page.
Elixinol Wellness has revised the acquisition terms for its subsidiary, The Healthy Chef, following the withdrawal of a major US distribution partner, resulting in reduced liabilities and enhanced liquidity by A$1 million. With a focus on the Australian market, supported by strong growth performance in November, Elixinol is aligning investments toward higher-margin opportunities and positioning itself for long-term sustainable growth and improved shareholder value.
The most recent analyst rating on (AU:EXL) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Elixinol Wellness stock, see the AU:EXL Stock Forecast page.
Elixinol Wellness Limited has released a report detailing the top holders of its listed options, which are priced at $0.02 and have a two-year expiration from the issue date. The report highlights that 10 Bolivianos Pty Ltd holds the largest share at 15.54%, followed by another significant holding of 13.54% by the same entity. This information provides insights into the company’s shareholder structure and potential influence on its strategic decisions.
The most recent analyst rating on (AU:EXL) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Elixinol Wellness stock, see the AU:EXL Stock Forecast page.
Elixinol Wellness Limited has announced a new application for the quotation of securities on the ASX, with a total of 218,796,310 options expiring on October 23, 2027, set to be issued on November 25, 2025. This move is likely to impact the company’s market presence and could influence investor sentiment as it expands its financial instruments.
The most recent analyst rating on (AU:EXL) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Elixinol Wellness stock, see the AU:EXL Stock Forecast page.
Elixinol Wellness Limited has announced the appointment of Gavin Evans as a director, effective December 2, 2025. Evans holds 50,000,000 unlisted options and 7,407,407 fully paid ordinary shares, indicating a significant stake in the company. This appointment may influence the company’s strategic direction and could impact its market positioning, potentially affecting stakeholders’ interests.
The most recent analyst rating on (AU:EXL) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Elixinol Wellness stock, see the AU:EXL Stock Forecast page.
Elixinol Wellness has announced the resignation of David Fenlon as Chair of the Board, with Gavin Evans stepping in as the new Independent Non-Executive Chair. Evans, who has a strong background in building profitable wellness businesses, has been a strategic adviser to Elixinol and is expected to drive the company’s transformation agenda towards profitability. His leadership is anticipated to enhance operational discipline and growth, benefiting stakeholders and supporting the company’s strategic goals.
The most recent analyst rating on (AU:EXL) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Elixinol Wellness stock, see the AU:EXL Stock Forecast page.